Neutrophil Elastase Promotes Linker Cleavage and Paclitaxel Release from an Integrin‐Targeted Conjugate
Open Access
- 19 November 2018
- journal article
- research article
- Published by Wiley in Chemistry – A European Journal
- Vol. 25 (7) , 1696-1700
Abstract
This work takes advantage of one of the hallmarks of cancer, that is, the presence of tumor infiltrating cells of the immune system and leukocyte‐secreted enzymes, to promote the activation of an anticancer drug at the tumor site. The peptidomimetic integrin ligand cyclo(DKP‐RGD) was found to accumulate on the surface of αvβ3 integrin‐expressing human renal cell carcinoma 786‐O cells. The ligand was conjugated to the anticancer drug paclitaxel through a Asn‐Pro‐Val (NPV) tripeptide linker, which is a substrate of neutrophil‐secreted elastase. In vitro linker cleavage assays and cell antiproliferative experiments demonstrate the efficacy of this tumor‐targeting conjugate, opening the way to potential therapeutic applications.Keywords
Funding Information
- Ministero dell’Istruzione, dell’Università e della Ricerca (PRIN 2015 project 20157WW5EH)
- European Commission (MSCA-ITN MAGICBULLET 642004)
- Università degli Studi di Milano
- Erasmus+
This publication has 61 references indexed in Scilit:
- Cancer-Targeted Delivery Systems Based on PeptidesFuture Medicinal Chemistry, 2018
- Current Trends in the Clinical Development of Antibody-Drug Conjugates in OncologyPharmaceutical Medicine, 2018
- Advances in targeting the folate receptor in the treatment/imaging of cancersChemical Science, 2017
- Modular Assembly of Reversible Multivalent Cancer‐Cell‐Targeting Drug ConjugatesAngewandte Chemie, 2017
- Modular Assembly of Reversible Multivalent Cancer‐Cell‐Targeting Drug ConjugatesAngewandte Chemie International Edition, 2017
- Strategies and challenges for the next generation of antibody–drug conjugatesNature Reviews Drug Discovery, 2017
- Synthesis of Novel c(AmpRGD)–Sunitinib Dual Conjugates as Molecular Tools Targeting the αvβ3 Integrin/VEGFR2 Couple and Impairing Tumor-Associated AngiogenesisJournal of Medicinal Chemistry, 2016
- Development of BT1718, a Bicycle Drug Conjugate® (BDC) targeting MT1-MMP for treatment of solid tumoursEuropean Journal of Cancer, 2016
- Antibody–Drug Conjugates: An Emerging Concept in Cancer TherapyAngewandte Chemie International Edition, 2014
- Antikörper-Wirkstoff-Konjugate: ein neues Konzept in der KrebstherapieAngewandte Chemie, 2014